Carl Zeiss Meditec AG : There is still some upside potential
Entry price | Target | Stop-loss | Potential |
---|
€54.7 |
€60 |
€52 |
+9.69% |
---|
The underlying tendency is to the upside for shares in Carl Zeiss Meditec AG and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● The group's high margin levels account for strong profits.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● Within the weekly time frame the stock shows a bullish technical configuration above the support level at 47.44 EUR
Weaknesses● The stock is close to a major daily resistance at EUR 54.4, which should be gotten rid of so as to gain new appreciation potential.
● With an enterprise value anticipated at 3.29 times the sales for the current fiscal year, the company turns out to be overvalued.
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.17 times its estimated earnings per share for the ongoing year.
● Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
● The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.